Strategic leadership Coating Place recently appointed Ajay Damani as president and secured strategic investment from 1315 Capital, signaling a growth-focused trajectory and potential expansion in capacity, offerings, and partnerships that sales teams can leverage to position services to larger pharma and nutraceutical clients.

Growth capital The $ growth capital infusion from 1315 Capital indicates available funding for scale-up projects, facility expansion, or new capability investments. This creates opportunities to offer expanded CDMO services such as more complex multiparticulate delivery systems or enhanced outsourcing packages.

Expanded governance Board addition and leadership changes can accelerate strategic initiatives and drive faster decision-making in collaborations, tech transfer, and scale-up programs. Engage early to align on milestones for new development programs or service expansions.

Technical depth With over five decades of expertise in multiparticululate delivery, Wurster fluid bed processing, ion exchange resins, and extrusion–spheronization, Coating Place is well-positioned to take on complex modified-release and taste-masking projects for pharma, nutraceutical, and animal health clients seeking specialized manufacturing partners.

Regulated capabilities FDA-registered, DEA-licensed, and GMP-compliant with capabilities for controlled substances and solvent-based processing provide a robust platform for cGMP manufacturing collaborations, including development, tech transfer, and commercial supply for solid oral dosage forms.